Rise Therapeutics, a clinical-stage biotechnology company, has announced the enrollment of the first patient in its Phase 1 clinical trial of R-2487 for rheumatoid arthritis (RA). This first-in-human trial is designed to evaluate the safety, pharmacodynamics, and clinical activity of R-2487 in patients with RA.
Gary Fanger, president and CEO of Rise Therapeutics, stated, "This is an important milestone for the company and patients suffering from rheumatoid arthritis. This achievement reinforces our commitment to deliver innovative new medicines to the clinical community."
Rheumatoid Arthritis: A Significant Unmet Need
Rheumatoid arthritis is a chronic, systemic inflammatory disorder affecting a substantial portion of the global population. Estimates suggest that up to 0.24% of the world population and as much as 1% of the US population are affected. The prevalence varies by geographical origin and gender, with women being approximately three times more likely to develop the condition than men. RA primarily targets the synovial joints, and approximately half of affected individuals experience disability as the disease progresses.
R-2487 Phase 1 Trial Details
The Phase 1 clinical trial (NCT05961592) is designed to assess the safety profile of R-2487, while also exploring its pharmacodynamics and potential clinical activity in RA patients. R-2487 is being developed as an oral immunotherapeutic medicine.
